174 related articles for article (PubMed ID: 38019511)
1. Aneurysm and Artery Dissection After Oral VEGFR-TKI Use in Adults With Cancer.
Kang S; Yeon B; Kim MS; Yoo M; Kim B; Yu YM
JAMA Netw Open; 2023 Nov; 6(11):e2345977. PubMed ID: 38019511
[TBL] [Abstract][Full Text] [Related]
2. Comparative evaluation of cardiovascular risks among nine FDA-approved VEGFR-TKIs in patients with solid tumors: a Bayesian network analysis of randomized controlled trials.
Hou W; Ding M; Li X; Zhou X; Zhu Q; Varela-Ramirez A; Yi C
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2407-2420. PubMed ID: 33725154
[TBL] [Abstract][Full Text] [Related]
3. Analysis of Anti-Angiogenesis-Related Adverse Events Associated with Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitors (VEGFR-TKIs) in Patients with Metastatic Renal Cell Carcinoma.
Lee N; Lee JL; Lee JY
Target Oncol; 2023 Mar; 18(2):247-255. PubMed ID: 36826462
[TBL] [Abstract][Full Text] [Related]
4. Bleeding with vascular endothelial growth factor tyrosine kinase inhibitor: A network meta-analysis.
Das A; Mahapatra S; Bandyopadhyay D; Samanta S; Chakraborty S; Philpotts LL; Jahangir E; Roy B
Crit Rev Oncol Hematol; 2021 Jan; 157():103186. PubMed ID: 33309571
[TBL] [Abstract][Full Text] [Related]
5. Assessment of Tyrosine Kinase Inhibitors and Survival and Cardiovascular Outcomes of Patients With Non-Small Cell Lung Cancer in Taiwan.
Chang WT; Lin HW; Chang TC; Lin SH; Li YH
JAMA Netw Open; 2023 May; 6(5):e2313824. PubMed ID: 37195663
[TBL] [Abstract][Full Text] [Related]
6. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis.
Qi WX; Sun YJ; Tang LN; Shen Z; Yao Y
Crit Rev Oncol Hematol; 2014 Mar; 89(3):394-403. PubMed ID: 24182420
[TBL] [Abstract][Full Text] [Related]
7. Using a zebrafish xenograft tumor model to compare the efficacy and safety of VEGFR-TKIs.
Wanting H; Jian Z; Chaoxin X; Cheng Y; Chengjian Z; Lin Z; Dan C
J Cancer Res Clin Oncol; 2023 Aug; 149(9):5975-5987. PubMed ID: 36609710
[TBL] [Abstract][Full Text] [Related]
8. Association of Fluoroquinolone Use With Short-term Risk of Development of Aortic Aneurysm.
Newton ER; Akerman AW; Strassle PD; Kibbe MR
JAMA Surg; 2021 Mar; 156(3):264-272. PubMed ID: 33404647
[TBL] [Abstract][Full Text] [Related]
9. Major adverse cardiovascular events of vascular endothelial growth factor tyrosine kinase inhibitors among patients with different malignancy: A systemic review and network meta-analysis.
Chen YC; Chen JH; Hsieh FI
J Chin Med Assoc; 2024 Jan; 87(1):48-57. PubMed ID: 37991373
[TBL] [Abstract][Full Text] [Related]
10. Vascular Endothelial Growth Factor Inhibitors and the Risk of Aortic Aneurysm and Aortic Dissection.
Wu CW; Huang HY; Lin SY; Wang CC; Huang CF; Wu IH
JAMA Netw Open; 2024 Mar; 7(3):e240940. PubMed ID: 38436956
[TBL] [Abstract][Full Text] [Related]
11. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Vano YA; Elaidi R; Bennamoun M; Chevreau C; Borchiellini D; Pannier D; Maillet D; Gross-Goupil M; Tournigand C; Laguerre B; Barthélémy P; Coquan E; Gravis G; Houede N; Cancel M; Huillard O; Beuzeboc P; Fournier L; Méjean A; Cathelineau X; Doumerc N; Paparel P; Bernhard JC; de la Taille A; Bensalah K; Tricard T; Waeckel T; Pignot G; Braychenko E; Caruso S; Sun CM; Verkarre V; Lacroix G; Moreira M; Meylan M; Bougouïn A; Phan L; Thibault-Carpentier C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C; Oudard S
Lancet Oncol; 2022 May; 23(5):612-624. PubMed ID: 35390339
[TBL] [Abstract][Full Text] [Related]
12. Oral adverse events in cancer patients treated with VEGFR-directed multitargeted tyrosine kinase inhibitors.
Yuan A; Kurtz SL; Barysauskas CM; Pilotte AP; Wagner AJ; Treister NS
Oral Oncol; 2015 Nov; 51(11):1026-1033. PubMed ID: 26403941
[TBL] [Abstract][Full Text] [Related]
13. Association of Fluoroquinolones With the Risk of Aortic Aneurysm or Aortic Dissection.
Gopalakrishnan C; Bykov K; Fischer MA; Connolly JG; Gagne JJ; Fralick M
JAMA Intern Med; 2020 Dec; 180(12):1596-1605. PubMed ID: 32897307
[TBL] [Abstract][Full Text] [Related]
14. Vascular Endothelial Growth Factor Receptor Inhibitors Impair Left Ventricular Diastolic Functions.
Yokoyama H; Shioyama W; Shintani T; Maeda S; Hirobe S; Maeda M; Sakata Y; Fujio Y
Int Heart J; 2021; 62(6):1297-1304. PubMed ID: 34853223
[TBL] [Abstract][Full Text] [Related]
15. Dose Intensity in Real-World Patients With Metastatic Renal Cell Carcinoma Taking Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitors.
Johnston H; Deal AM; Morgan KP; Patel B; Milowsky MI; Rose TL
Clin Genitourin Cancer; 2023 Jun; 21(3):357-365. PubMed ID: 37012148
[TBL] [Abstract][Full Text] [Related]
16. Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors.
van Cann T; Loyson T; Verbiest A; Clement PM; Bechter O; Willems L; Spriet I; Coropciuc R; Politis C; Vandeweyer RO; Schoenaers J; Debruyne PR; Dumez H; Berteloot P; Neven P; Nackaerts K; Woei-A-Jin FJSH; Punie K; Wildiers H; Beuselinck B
Support Care Cancer; 2018 Mar; 26(3):869-878. PubMed ID: 28963584
[TBL] [Abstract][Full Text] [Related]
17. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
Koo DH; Park I; Ahn JH; Lee DH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Lee JL
Cancer Chemother Pharmacol; 2016 Feb; 77(2):339-47. PubMed ID: 26687171
[TBL] [Abstract][Full Text] [Related]
18. Clinical impact of early response to first-line VEGFR-TKI in patients with metastatic renal cell carcinoma on survival: A multi-institutional retrospective study.
Sobu R; Numakura K; Naito S; Hatakeyama S; Kato R; Koguchi T; Kojima T; Kawasaki Y; Kandori S; Kawamura S; Arai Y; Ito A; Nishiyama H; Kojima Y; Obara W; Ohyama C; Tsuchiya N; Habuchi T
Cancer Med; 2023 Feb; 12(4):4100-4109. PubMed ID: 36200612
[TBL] [Abstract][Full Text] [Related]
19. Cardiovascular Toxicities of Antiangiogenic Tyrosine Kinase Inhibitors: A Retrospective, Pharmacovigilance Study.
Goldman A; Bomze D; Dankner R; Fourey D; Boursi B; Arad M; Maor E
Target Oncol; 2021 Jul; 16(4):471-483. PubMed ID: 33970401
[TBL] [Abstract][Full Text] [Related]
20. Congestive heart failure with vascular endothelial growth factor receptor tyrosine kinase inhibitors.
Ghatalia P; Morgan CJ; Je Y; Nguyen PL; Trinh QD; Choueiri TK; Sonpavde G
Crit Rev Oncol Hematol; 2015 May; 94(2):228-37. PubMed ID: 25577572
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
